Distinct gene expression-defined classes of gastrointestinal stromal tumor

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4100-4108

  Yamaguchi, Umio ^a   Nakayama, Robert ^a   Honda, Kazufumi ^a   Ichikawa, Hitoshi ^a   Hasegawa, Tadashi ^a   Shitashige, Miki ^a   Ono, Masaya ^a   Shoji, Ayako ^a   Sakuma, Tomohiro ^a   Kuwabara, Hideya ^a   Shimada, Yasuhiro ^a   Sasako, Mitsuru ^a   Shimoda, Tadakazu ^a   Kawai, Akira ^a   Hirohashi, Setsuo ^a   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE PROBE; GENETICS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; STOMACH; T LYMPHOCYTE ACTIVATION; TUMOR CLASSIFICATION; TUMOR GROWTH; VALIDATION PROCESS;

ANTIGENS, CD26; CLUSTER ANALYSIS; COILED BODIES; GASTROINTESTINAL STROMAL TUMORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 51649106775     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2331     Document Type: Article

References (38)

1. Miettinen M, Lasota J: Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 438:1-12, 2001
2. Kitamura Y, Hirota S, Nishida T: Gastrointestinal stromal tumors (GIST): A model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 94:315-320, 2003
3. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal stromal tumors. J Clin Oncol 22:3813-3825, 2004
4. Kindblom LG, Remotti HE, Aldenborg F, et al: Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259-1269, 1998
5. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
6. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
7. Hirota S, Ohashi A, Nishida T, et al: Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 125:660-667, 2003
8. Hasegawa T, Matsuno Y, Shimoda T, et al: Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 33:669-676, 2002
9. Taniguchi M, Nishida T, Hirota S, et al: Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59:4297-4300, 1999
10. DeMatteo RP, Lewis JJ, Leung D, et al: Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 231:51-58, 2000
11. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459-465, 2002
12. Miettinen M, El-Rifai W, Sobin LH, et al: Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Hum Pathol 33:478-483, 2002
13. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
14. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study. Lancet 358:1421-1423, 2001
15. Heinrich MC, Corless CL, Demetri GD, et al: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342-4349, 2003
16. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472-480, 2002
17. Verweij J, van Oosterom A, Blay JY, et al: Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39:2006-2011, 2003
18. Chen LL, Trent JC, Wu EF, et al: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64:5913-5919, 2004
19. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
20. von Mehren M: Beyond imatinib: Second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer 6:S30-S34, 2006 (suppl 1)
21. Yamaguchi U, Hasegawa T, Masuda T, et al: Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch 445:142-150, 2004
22. Yamaguchi U, Hasegawa T, Sakurai S, et al: Interobserver variability in histologic recognition, interpretation of KIT immunostaining, and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. Appl Immunohistochem Mol Morphol 14:46-51, 2006
23. Sakurai S, Hasegawa T, Sakuma Y, et al: Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: A subtype of GIST with mutations of platelet-derived growth factor receptor α gene. Hum Pathol 35:1223-1230, 2004
24. Shitashige M, Naishiro Y, Idogawa M, et al: Involvement of splicing factor-1 in β-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology 132:1039-1054, 2007
25. Honda K, Yamada T, Hayashida Y, et al: Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128:51-62, 2005
26. Aickin M, Gensler H: Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods. Am J Public Health 86:726-728, 1996
27. Allander SV, Nupponen NN, Ringner M, et al: Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 61:8624-8628, 2001
28. Subramanian S, West RB, Corless CL, et al: Gastrointestinal stromal tumors (GIST) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 23:7780-7790, 2004
29. Antonescu CR, Viale A, Sarran L, et al: Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282-3290, 2004
30. Kang HJ, Nam SW, Kim H, et al: Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24:1066-1074, 2005
31. Price ND, Trent J, El-Naggar AK, et al: Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104:3414-3419, 2007
32. Weinstein JN, Myers TG, O'Connor PM, et al: An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349, 1997
33. Pro B, Dang NH: CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol 19:1345-1351, 2004
34. Aratake Y, Kotani T, Tamura K, et al: Dipeptidyl aminopeptidase IV staining of cytologic preparations to distinguish benign from malignant thyroid diseases. Am J Clin Pathol 96:306-310, 1991
35. Hirai K, Kotani T, Aratake Y, et al: Dipeptidyl peptidase IV (DPP IV/CD26) staining predicts distant metastasis of 'benign' thyroid tumor. Pathol Int 49:264-265, 1999
36. Ho L, Aytac U, Stephens LC, et al: In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7:2031-2040, 2001
37. Herman GA, Bergman A, Liu F, et al: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46:876-886, 2006
38. Idris I, Donnelly R: Dipeptidyl peptidase-IV inhibitors: A major new class of oral antidiabetic drug. Diabetes Obes Metab 9:153-165, 2007